| Emerald Coast Podiatry | |
|
849 S Three Notch St, Andalusia, AL 36420-5325 | |
| (850) 682-6522 | |
| Not Available |
| Full Name | Emerald Coast Podiatry |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 849 S Three Notch St, Andalusia, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295197093 | NPI | - | NPPES |
| 340598200 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emerald Coast Podiatry 120 E Redstone Ave, Crestview, FL 32539-5370 Ph: (850) 682-6522 | Emerald Coast Podiatry 849 S Three Notch St, Andalusia, AL 36420-5325 Ph: (850) 682-6522 |
News Archive
The American Thoracic Society applauds the collaborative effort of President Barack Obama and Prime Minister Justin Trudeau of Canada to reduce methane emissions from the oil and natural gas sector. Methane is a powerful greenhouse gas that contributes to global climate change.
Children who have cochlear implants (CI) rank their quality of life (QOL) equal to their normally hearing (NH) peers, indicates new research in the February 2010 issue of Otolaryngology - Head and Neck Surgery.
Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.
PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).
Findings from the largest survey ever conducted on the co-occurrence of psychiatric disorders among U.S. adults indicates a sharper picture than previously reported of major depressive disorder (MDD) in specific population groups.
› Verified 3 days ago